BioSpace News Archive

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience Company thanks Director Robert W. Pangia as he retires from the Board

Today, the U.S. Food and Drug Administration authorized marketing of the GI Genius, the first device that uses artificial intelligence (AI) based on machine learning to assist clinicians in detecting lesions (such as polyps or suspected tumors) in the colon in real time during a colonoscopy

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“ IntelGenx ”), a leader in pharmaceutical films, today announced that it is proposing to amend the terms of its 6.0% convertible unsecured promissory notes due June 1, 2021, originally issued by private placement on May 8, 2018

Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, will display multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021.

- The Prime Minister, Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date April 9, 2021 Time 11:30 AM (EDT) Location

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”

Moderna to Present at the 20 th Annual Needham Virtual Healthcare Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET

Some panel members also recommended preferential use of REGEN-COV antibody cocktail in regions where certain variants are common

Cansortium Inc. (“Cansortium” or the “Company”) (CSE: TIUM.U), (OTCQB: CNTMF), today announced the second and final closing of its previously announced private placement of units (“Units”) at a purchase price of US$0.70 per Unit (the “Private Placement”)